Phase Forward to Present at DIA 15th Annual European Clinical Data Management Conference

Phase Forward (NASDAQ: PFWD) -- Company Experts to Lead Dialogue on the Use of Industry Standards and Review Technology Advancements that Enable the Acceleration of Global EDC Adoption --
Who: Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety

What: Drug Information Association Annual European Clinical Data
Management Conference, Four Worlds - One Vision: Delivering
Quality Data Effectively

When: Sunday, November 6, through Wednesday, November 9, 2005

Where: Prague Congress Centre, Czech Republic

The Drug Information Association (DIA) is a non-profit,multidisciplinary, neutral forum for sharing information thatoptimises the process of drug development and lifecycle management.This year's European Clinical Data Management conference has beendesigned to explore the interface and integration of clinical datamanagement, eClinical, information technology, and validation.

As part of this year's conference, Phase Forward professionals JonCarrano, Australian Office Head, and Mark Wren, Director eServices,will deliver presentations as part of the following sessions:

-- "Clinical Data Management Standards"

This session will address the concept of standardisation andpractical applications of HL7 and CDISC. Experience will be sharedwith respect to the integration of hospital and CRO data into theclinical database. Jon Carrano will deliver a presentation entitled,"HL7 Data Integration of Clinical Trials & Hospital Data." Wednesday,November 9, 8:30 AM.

-- "EDC Experiences"

This session will review the results of the first year of datafrom over 100 Central and Eastern European sites using electronic datacapture (EDC), together with a discussion of the key factorsinfluencing the successful use of EDC in these regions. The sessionwill also cover some of the information technology experiences, thechallenges faced, and the solutions found while conducting andvalidating a large EDC undertaking. Further, experiences will bepresented from conducting studies globally - the language of culturaldiversity, global investigator adoption, and impact of localregulatory requirements. Mark Wren will deliver a presentationentitled, "EDC: The Global Crusade - From Argentina to Zambia."Wednesday, November 9, 1:30 PM.

In addition to these DIA sponsored sessions, Phase Forward willhost a complimentary hospitality event titled, "Signal Detection inClinical Trial Data and Integrated Trial Management EDC." The eventwill provide insight into signal detection in clinical data combinedwith an update on the benefits of electronic data capture. WilliamBlackwell from Lincoln Technologies will showcase the Clinical TrialSignal Detection (CTSD) and WebSDM(TM) (Web Submission Data Manager)products - industry leading technologies enabling companies to performsignal detection on their own clinical databases, managing risk fromthe start of their clinical trial programmes. Phase Forward willpresent some of the key clinical research activities that theInForm(TM) EDC solution addresses and highlight the improvements andbenefits that can be harnessed by all users. The event will be held atthe Holiday Inn Hotel, Prague (adjacent to the Congress Centre) onTuesday, November 8, from 6:00 PM - 8:00 PM.

Attendees are also invited to visit Phase Forward at Booth #39-40to learn more about the company's clinical data management solutions,including the latest version of its award-winning EDC solution,InForm(TM) ITM, which provides clinical organizations with the abilityto enhance the execution and management of clinical trials, improveand accelerate clinical decision-making, and realize increased costsavings.

For media inquiries, please contact Brian Gendron of SHIFTCommunications at 617-681-1226.

About Phase Forward

Phase Forward is a leading provider of integrated data managementsolutions for clinical trials and drug safety. The company offersproven solutions in electronic data capture (EDC), clinical datamanagement (CDM), and adverse event reporting (AER) to helppharmaceutical, biotechnology, and medical device companies bringneeded drugs and therapies to market faster and more safely. LincolnTechnologies, acquired by Phase Forward in August of 2005, deliverssolutions for pharmacovigilance, data standardization, and safetysignal detection. The combined companies' products and services havebeen utilized in over 10,000 clinical trials involving more than1,000,000 clinical trial study participants at over 220 organizationsand regulatory agencies worldwide including: AstraZeneca, Biogen Idec,Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, FDA,GlaxoSmithKline, Guidant, MHRA, NIH, Procter & Gamble, Quintiles,Sanofi-Aventis, Schering-Plough Research Institute, and Serono.Additional information about Phase Forward is available atwww.phaseforward.com.

Certain statements made in this press release that are not basedon historical information are forward-looking statements which aremade pursuant to the safe harbor provisions of the Private SecuritiesLitigation Reform Act of 1995. This press release contains express orimplied forward-looking statements relating to, among other things,the performance of Phase Forward's products and services, continuedmarket acceptance of Phase Forward's products and services, and theability of Phase Forward's customers to realize benefits from the useof Phase Forward's products and services. These statements are neitherpromises nor guarantees, but are subject to a variety of risks anduncertainties, many of which are beyond Phase Forward's control, whichcould cause actual results to differ materially from thosecontemplated in these forward-looking statements. In particular, therisks and uncertainties include, among other things, the ability ofPhase Forward's customers to realize benefits from the use of itsproducts and services, the possibility that customers' needs or plansmay change over time, and the introduction or improvement of productsand services competitive with those of Phase Forward. Existing andprospective investors are cautioned not to place undue reliance onthese forward-looking statements, which speak only as of the datehereof. Phase Forward undertakes no obligation to update or revise theinformation contained in this press release, whether as a result ofnew information, future events or circumstances or otherwise. Foradditional disclosure regarding these and other risks faced by PhaseForward, see the disclosure contained in Phase Forward's publicfilings with the Securities and Exchange Commission including, withoutlimitation, its most recent Quarterly Report on Form 10-Q.